Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room

NCT01857947 is registered in ClinicalTrials.gov with ThermoFisher Scientific Brahms Biomarkers France as lead sponsor.

NCT NCT01857947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01857947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room
Lead sponsor
ThermoFisher Scientific Brahms Biomarkers France
Phase
Not applicable
Overall status
Completed
Start date
March 31, 2013
Completion date
December 31, 2014
Enrollment
370 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive patients admitted in emergency department for acute exacerbation